Study Summary
This trial is testing whether it is safe to reduce the time patients are on two blood-thinning medications after having a coronary stent placed.
- Bleeding Complications
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 0 Secondary · Reporting Duration: Through study completion, approximately 90 days.
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
Conventional Therapy
1 of 2
Genotype-Guided Therapy
1 of 2
Active Control
Experimental Treatment
150 Total Participants · 2 Treatment Groups
Primary Treatment: Tricagrelor · No Placebo Group · Phase 4
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
How many individuals have enrolled in the research trial?
"Confirmed. The clinical trial is actively recruiting according to the data hosted on clinicaltrials.gov, which was first posted on March 29th 2022 and most recently updated October 24th 2022. 150 prospective participants are needed from a single medical facility." - Anonymous Online Contributor
Is enrollment in this research study still a viable option for those seeking treatment?
"Affirmative. Details obtained from clinicaltrials.gov demonstrate that the clinical trial, which was first advertised on March 29th 2022, is actively recruiting patients. 150 volunteers are required at a single location to participate in this research endeavour." - Anonymous Online Contributor
Is the drug Tricagrelor officially certified by the FDA?
"As this is a phase 4 trial, there are numerous studies that have validated tricagrelor's safety and efficacy; thus we assign it a score of 3." - Anonymous Online Contributor